The Patented Medicines (Notice of Compliance) Regulations regulations link the patent system to the regulatory regime for food and drugs in Canada.
- Filter by
- Categories
- Tags
- Show all
- Article
- Confusion
- Contract
- Copyright
- Corporate
- Domain Names
- Employment
- Expungement
- Expungement
- Grey Marketing
- Industrial Designs
- Licensing
- Obviousness
- Opposition
- Passing Off
- Patent
- Patent Infringement
- Patent Strategy
- PM(NOC)
- Procedure
- Prosecution
- recognition
- Services
- Summary
- Trade Secrets
- Trade-mark
- Use
- Validity
- 35 US Code §101
- 3D printing
- Abandonment
- abstract theorems
- Abuse of Process
- Accounting of Profits
- acquired distinctiveness
- actions
- actual notice
- agreement
- Alice/Mayo Test
- Ambiguity
- Amendments
- Anticipation
- Appeal
- Apple
- application
- application fee
- arbitrary
- arbitration
- Artificial Intelligence
- Assignment
- Australia
- Bad Faith
- Bargain Theory
- Bill C-31
- Bill C-43
- Bill C-8
- Bill C-86
- Biologics
- biosimilar
- Biotech Patents
- Blockchain
- border measures
- Brand
- broadcasting
- budget
- burden of proof
- business
- CAFC
- Canada
- Canada Gazette
- Cannabis Law
- causal link
- cdrp
- CEEO
- Certificate of Supplementary Protection
- champerty
- Chemical Patent
- chemistry
- ciba
- CIPO
- CIPO errors
- CIRA
- Claim Construction
- Class Actions
- clerical error
- collateral estoppel
- College of Patent Agents and Trademark Agents
- combination drugs
- commissioner
- Common General Knowledge
- Complete Code
- Confidential Information
- confidentiality
- confidentiality order
- Conflict of Interest
- Confusion
- Constitution
- consumer goods
- contract
- contributory infringement
- Copyright
- Copyright Infringement
- copyright test
- corrections
- Costs
- counterfeit
- Court of Appeals for the Federal Circuit
- COVID-19
- CSP
- cybersecurity
- Damages
- Data
- Data Protection
- deadline
- defamation
- defences
- Delay to Market Entry
- descriptive
- Design Patents
- deviation
- digital infringement
- disclosure
- Discovery
- Distinctiveness
- Diversity
- division of powers
- divisionals
- DNA Patents
- domain names
- dominant feature
- Dosage Range
- Double Patenting
- doubtful cases
- Due Care
- Duty of Candor
- E-Commerce
- Early dismissal
- economics
- Employment
- errors
- essentiality of elements
- Ethics
- Europe
- Events
- Evidence
- examination quality
- examination statistics
- Examiner
- Expedited Examination
- Expert Blinding
- Expert Evidence
- expiry
- Expungement
- extraterritoriality
- Fair Use
- federal circuit
- Federal Court
- Federal Court of Appeal
- fees
- file wrapper
- Filing
- filing date
- filing fee
- financial services
- Food and Drug Regulations
- Foreign Filing License
- foreign issue estoppel
- forum selection
- fraud
- Free World Trust
- frivolous
- funding
- future infringement
- generics
- geographical indications
- Good Faith
- goods
- Government
- Grace Period
- grey marketing
- Hague
- Hatch-Waxman
- Health Canada
- Hearsay
- Honest Contractual Performance
- ICSID
- Improver
- Indefiniteness
- Inducement
- Industrial Designs
- inherent distinctiveness
- Injunction
- Injunctions
- Innovation
- Innovative Drugs
- Insufficient Disclosure
- Intellectual Property
- intent
- Inter Partes Review
- interlocutory injunction
- Internet
- Internship
- Investors
- IP Lawyer
- IP Strategy
- IPIC
- IPO
- ISP
- IT patent
- ITC
- Jurisdiction
- Late fee
- Legal Retainer
- legal test
- Legislative Reform
- Liability
- Licensing
- life science
- limitation periods
- Litigation
- litigation funding agreement
- Madrid Protocol
- Maintenance Fee
- Marking Requirement
- materiality
- medical
- method
- Methods of Medical Treatment
- misleading
- motion
- Motion to dismiss
- Motion to strike
- NAFTA
- national phase entry
- Natural Health Product
- new evidence
- Non-Infringing Alternative
- Non-Practicing Entity
- notice of allegation
- notice to rectify
- Novelty
- obivous error
- Obviousness
- Official Marks
- On-Sale Bar
- ontario
- Overbreadth
- Ownership & Inventorship
- Passing Off
- Patent Act
- Patent Agents
- Patent Appeal Board
- Patent Application
- Patent Drafting
- Patent Infringement
- Patent Litigation
- Patent Office
- patent office errors
- patent prosecution
- patent requirement
- Patent Rules
- Patent Strategy
- Patent Term Adjustment
- Patent Textbook
- Patent Trial and Appeal Board
- Patent Trolls
- patentability
- Patentable Subject Matter
- Patents
- PCT
- Pharmaceutical Patent
- Pharmaceutical Pricing
- PLT
- PM(NOC)
- PM(NOC) Damages
- PMPRB
- POSITA
- pride
- prior art
- Prior Disclosure
- prior use
- Priority
- Privilege
- procedure
- Product Specificity
- prohibited marks
- Promise Doctrine
- proprietor
- Prosecution
- Prosecution History
- protective order
- prothonotaries
- Provisional Patent
- public sale
- Public Servant
- Punitive Damages
- Recognition
- registration
- Reinstatement
- Reissue
- Remedies
- representation
- request for correction
- requisition
- responding
- review
- risk
- Royalties
- s. 27
- s. 45
- s. 53
- sale
- Scheduling
- Scholarship
- SCOTUS
- second person
- Secondary Infringement
- secondary meaning
- secret sale
- Section 45
- security
- Selection Patents
- Services
- settlement
- Site-Blocking Orders
- skilled person
- Software
- Software Copyright
- Software Patent
- Sound Prediction
- Specification
- sponsorship
- Springboard Profits
- SRED
- Standard of Proof
- Standard of Review
- Standard-Essential Patents
- standing
- standing to appeal
- Start-up
- Startups
- Statute of Monopolies
- stay
- Strategy
- Sufficiency
- Summary Judgment
- superior court
- Supreme Court of Canada
- surname
- Technology
- Telecommunications
- time frame
- TPP
- Trade Secrets
- Trademark
- Trademark Infringement
- Trademark Licensing
- Trademark Opposition
- Trademark Trial and Appeal Board
- Trademarks Act
- treaty
- UK
- United Kingdom
- United States
- Use
- useful article
- USMCA
- USPTO
- Utility
- Validity
- Variant
- Velocity
- vexatious
- who's who legal
- Written Description
March 10, 2014
March 10, 2014
Valeant Canada LP v Canada (Health), 2014 FCA 50 - The Court dismissed an appeal from the Federal Court’s decision to grant Valeant’s motion to disqualify Cobalt’s in-house lawyer from any further involvement in the application before the Court on the ground that he could be presumed to have Valeant’s confidential information.
January 23, 2014
January 23, 2014
AbbVie Corporation v Janssen Inc. [2014 FC 55] Background The action is in respect of a patent directed to human antibodies capable of binding a […]
January 7, 2014
January 7, 2014
Alcon Canada Inc. v Apotex Inc. [2012 FC 410] Background The patent at issue is Canadian Patent 2,195,094. The patent is for a topical ophthalmic […]
January 7, 2014
January 7, 2014
Gilead Sciences Inc. v Canada (Health) [2013 FC 1270] Bristol-Myers Squibb v Canada(Health) [2013 FC 1271] Gilead Sciences Inc. v Canada(Health) [2013 FC 1272] Background […]
December 23, 2013
December 23, 2013
Apotex Inc. v Takeda Canada Inc. 2013 FC 1237 Background This is an application under section 8 of the PM(NOC) process dealing with lost revenue […]
October 24, 2013
October 24, 2013
Mylan Pharmaceuticals ULC v Bristol-Myers Squibb Canada Co. [2013 FCA 231] Background This is an appeal of a cost award from a Judgment of Justice Barnes […]
September 16, 2013
September 16, 2013
Apotex Inc. v Abbot Laboratories Ltd. Takeda Pharmaceuticals Company Ltd. And Takeda Pharmaceuticals America Inc. 2013 ONCA 555 Apotex appealed the dismissal of its unjust […]
August 14, 2013
August 14, 2013
Eli Lilly Canada Inc. v. Novopharm Limited – 2013 FC 677 Per Prothonotary Tabib: In this motion Teva sought to amend its Statement of Defence and […]
July 24, 2013
July 24, 2013
Hoffman-La Roche Limited v. Apotex Inc., 2013 FC 718 In this application brought under the PM(NOC) Regulations Roche sought to prohibit the Minister of Health from […]
June 7, 2013
June 7, 2013
Bayer Inc. v. Cobalt Pharmaceuticals, 2013 FC 573 Bayer sought an order prohibiting the Minister of Health from issuing a Notice of Compliance (NOC) to Cobalt, […]
May 29, 2013
May 29, 2013
Apotex Inc. v Pfizer Canada Inc. – 2013 FC 493 Apotex claimed damages under s. 8 of the PM(NOC) Regulations on grounds that it incurred a […]
March 26, 2013
March 26, 2013
Novartis Pharmaceuticals Canada Inc. v. Teva Canada Limited, 2013 FC 283 Novartis brought two applications under the provisions of the PM(NOC) Regulations to restrain the Minister […]
March 13, 2013
March 13, 2013
AstraZeneca Canada Inc. v. Apotex Inc., 2013 FCA 77 AstraZeneca appeals the trial court’s decision in a proceeding commenced by Apotex under s. 8 of the […]
March 13, 2013
March 13, 2013
AstraZeneca Canada Inc. v. Teva Canada Limited, 2013 FC 245 AstraZeneca seeks an order prohibiting the Minister of Health from issuing a Notice of Compliance to […]
February 27, 2013
February 27, 2013
Apotex Inc. v. Eli Lilly, 2013 ONSC 1135 (Div. Ct.) Lilly sought leave to appeal from a decision of Justice J. Macdonald of the Ontario Superior […]
February 11, 2013
February 11, 2013
Pfizer Canada et al. v. Pharmascience Inc., 2013 FC 120 Pfizer brought an application under the PM(NOC) Regulations to prohibit the Minister of Health from issuing […]
January 29, 2013
January 29, 2013
Eli Lilly Canada Inc. v. Teva Canada Limited – 2013 FC 28 This application was brought by Eli Lilly Canada under the PM(NOC) Regulations, seeking an […]
January 29, 2013
January 29, 2013
Apotex Inc. v. Canada (Health), 2012 FCA 322 Apotex commenced an application for judicial review of the Minister of Health’s treatment of its submission for a […]
January 22, 2013
January 22, 2013
Apotex Inc. v. Abbott Laboratories Limited, 2013 ONSC 356 In this case, Apotex claimed damages against Abbott Laboratories and Takeda Pharmaceuticals based on unjust enrichment. On […]